期刊
CLINICAL PHARMACOLOGY & THERAPEUTICS
卷 87, 期 1, 页码 13-15出版社
WILEY
DOI: 10.1038/clpt.2009.225
关键词
-
资金
- NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UH3TR000491, UH2TR000491] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF MENTAL HEALTH [R41MH093302, R42MH093302] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS077236, R01NS078307] Funding Source: NIH RePORTER
- NCATS NIH HHS [UH3 TR000491, UH2 TR000491] Funding Source: Medline
- NIMH NIH HHS [R41 MH093302, R42 MH093302] Funding Source: Medline
- NINDS NIH HHS [R01 NS078307, R21 NS077236] Funding Source: Medline
Drug resistance remains an unmet challenge in a variety of neurological disorders, but epilepsy is probably the refractory disease that has received most experimental, preclinical, and therapeutic attention. Although resective surgery continues to improve our ability to provide seizure relief, new discoveries have potential as alternative therapeutic approaches to multiple drug resistance. As discussed here, the field is replete with controversies and false starts, in particular as it concerns the existence of genetic predisposition to inadequate pharmacological seizure control.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据